Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one
Contents

Academy · Research Writing · Device material selection

Selecting Materials for a Medical Device: Biological Evaluation Requirements under ISO 10993-1

Material selection for a medical device is fundamentally a regulatory decision as well as an engineering one. ISO 10993-1 does not provide a test list; it requires the device to be categorised by the nature and duration of body contact, followed by a justification of which biological endpoints are addressed and how. An incorrect categorisation means that the entire evaluation rests on the wrong matrix.

Pubrica AcademyWritten by the medical writing and biostatistics teams Reviewed byPubrica biostatistics team Published9 October 2026 Last checked9 October 2026 Reading time12 minutes Sources26 peer-reviewed

Many material files reviewed by Pubrica fail at the same point. The alloy or polymer is a reasonable choice and the mechanical data are adequate, but the biocompatibility section states only that the device was evaluated “in accordance with ISO 10993”. That statement is uninformative to a reviewer, because ISO 10993-1 is a framework for a risk-based evaluation rather than a pass mark. A reviewer requires the contact categorisation, the endpoint set that follows from it, and a written justification for every endpoint not tested. This article sets out how to construct that argument from the material upward.

Learning objectives

  • Categorisation of a device by nature and duration of body contact under ISO 10993-1, and the reasons this decision determines all subsequent steps
  • The biological endpoints that follow from each contact category, and the justification of an endpoint addressed by existing data rather than new testing
  • The reasons implantation beyond 30 days alters the degradation and chronic-toxicity question
  • The way in which mechanical duty, of the order of 1 × 107 loading cycles over twenty years, constrains the material shortlist before biocompatibility is considered
  • Differences between FDA and EU MDR 2017/745 requirements for the same material dossier
  • The structure of a biological evaluation paragraph that specifies the endpoint set rather than merely citing the standard

Common misconceptions

  • “ISO 10993 is a list of tests that must be run.” ISO 10993-1 requires a biological evaluation conducted within a risk management process. The endpoint matrices are a starting point for that assessment, not a checklist to be completed mechanically, and FDA’s 2023 guidance on the use of ISO 10993-1 is explicit that existing data and chemical characterisation can address an endpoint where the justification holds.
  • “A material with a long history of use is pre-qualified.” Biological response depends on the finished, sterilised device in its contact configuration rather than on the raw material. The same alloy with a different surface finish or a different cleaning agent residue requires a separate evaluation.
  • “Titanium is titanium.” Ti-6Al-4V accounts for roughly 45% of titanium-based bioimplant production, per Kang and Fang in Advances in Manufacturing, and its alloying elements, grade and processing history all carry into the toxicological argument.
  • “If FDA accepts it, Europe will.” The instruments differ. FDA’s guidance governs how it reviews biological evaluation in a premarket submission; EU MDR 2017/745 sets general safety and performance requirements in its Annex I, including specific obligations where a device contains substances of concern. Clearance in one market is evidence, not equivalence.

Regulatory consequences of the material decision

A material choice fixes four things at once, and usually only the first is discussed in design review. It fixes the mechanical envelope — what the device can carry, and for how long, before it fails. It fixes the biological evaluation that will have to be funded, because the endpoint set follows from contact and duration rather than from the material’s reputation. It fixes the manufacturing and sterilisation route, since residues and process aids from that route become part of the toxicological argument. Finally, it fixes the supply chain, which is where change control eventually has consequences: a resin grade substitution three years into production reopens the chemical characterisation.

Kang and Fang, writing in Advances in Manufacturing, set out the practical constraints for load-bearing bioimplants 21. Stainless steels used in implants contain at least 10.5% chromium by mass, which is what gives the passive oxide film its corrosion resistance; Ti-6Al-4V accounts for about 45% of total titanium-based bioimplant production 21. These are not neutral facts for a dossier. Chromium content bears directly on the corrosion and ion-release question that a reviewer will raise, and the dominance of one alloy means that the toxicological comparison set is well populated — which is helpful, provided that finished devices rather than raw stock are being compared.

Scale is a reason for rigour rather than a source of reassurance. Al-Zyoud and colleagues, in Materials, note that the number of Brånemark System implants administered worldwide had reached 7 million by 2012. A material decision at that volume is irreversible in practice.

10.5%minimum chromium content by mass in implant stainless steels
45%share of titanium-based bioimplant production that is Ti-6Al-4V
1 × 107estimated loading cycles over 20 years, setting the fatigue requirement

Material constraints for load-bearing bioimplants. Source: Kang CW, Fang FZ. State of the art of bioimplants manufacturing: part I. Advances in Manufacturing.

Contact category and duration as the determining decision

ISO 10993-1 organises biological evaluation around two axes 2. The first is the nature of body contact: surface-contacting devices (skin, mucosal membrane, breached or compromised surfaces), externally communicating devices (blood path indirect, tissue/bone/dentin, circulating blood), and implant devices (tissue/bone, blood). The second is duration of contact: limited (up to 24 hours), prolonged (over 24 hours up to 30 days) and long-term (over 30 days) 9. Each device occupies exactly one cell of that grid, and the applicable endpoints follow from that cell.

This is the point at which most files fail, and the error is almost always optimistic. A catheter described as “short-term” in the engineering file may have an indicated dwell time exceeding 24 hours. An implant described as “temporary” may be intended to remain for six weeks. The categorisation must reflect the indication for use as written in the labelling, including the worst case a clinician could reasonably follow, not the typical case. If a reviewer disagrees with the categorisation, every endpoint decision downstream of it is reopened.

FDA’s 2023 guidance on the use of ISO 10993-1 describes how the Agency applies the standard in premarket review, and includes endpoint tables keyed to that same contact-and-duration grid 2. It should be read alongside the standard rather than in place of it: the guidance also sets out what FDA expects to see when an endpoint is addressed by chemical characterisation and toxicological risk assessment rather than by a biological test. The current version and any device-specific guidance should be confirmed with the regulatory affairs function before a test plan is fixed — guidance documents are revised, and this article describes what they require rather than certifying that a given plan satisfies them.

The two axes that determine the endpoint set

AxisCategoriesWhat it changesWhere it is defined
Nature of body contactSurface-contacting (intact skin, mucosal membrane, breached or compromised surface); externally communicating (indirect blood path, tissue/bone/dentin, circulating blood); implant (tissue/bone, blood)Which endpoint families are applicable at all — haemocompatibility, for example, only where there is blood contactISO 10993-1, as applied in FDA’s 2023 guidance on the use of ISO 10993-1
Duration of contactLimited (up to 24 hours); prolonged (over 24 hours up to 30 days); long-term (over 30 days)Whether degradation characterisation and the chronic end of the toxicology set come into scopeISO 10993-1; biodegradation testing treated as essential beyond 30 days by Al-Zyoud and colleagues in Materials
Device class (separate question)US: determined by classification regulation and submission route; EU: determined by the Annex VIII rules of EU MDR 2017/745Conformity assessment route and clinical evidence expectation — and it can differ between jurisdictions for the same device21 CFR device classification regulations; EU MDR 2017/745 Annex VIII

Categories as set out in ISO 10993-1 and in FDA’s 2023 guidance on the use of that standard; the 30-day biodegradation threshold as stated by Al-Zyoud and colleagues in Materials. Classification rules differ by jurisdiction; confirm the applicable class and route with your regulatory affairs function.

Biological endpoints and the justification of untested endpoints

The endpoint families are stable across contact categories, and only the applicable subset changes 9. Material characterisation under ISO 10993-18 and toxicological risk assessment under ISO 10993-17 underpin the rest. Cytotoxicity (ISO 10993-5), irritation and skin sensitisation (ISO 10993-10), acute systemic toxicity and material-mediated pyrogenicity (ISO 10993-11), and local effects after implantation (ISO 10993-6) appear widely. Genotoxicity, carcinogenicity and reproductive toxicity (ISO 10993-3) and chronic toxicity become relevant as duration extends. Haemocompatibility (ISO 10993-4) applies only where there is blood contact — and stating this explicitly is better practice than leaving the row blank.

What distinguishes a strong file is the treatment of endpoints that have not been tested. ISO 10993-1 permits an endpoint to be addressed with existing data where the justification is sound, and that justification must be written per endpoint, naming the data relied upon and explaining why they transfer to this device in this contact configuration 2. “The material is widely used” is not that justification. “The extractables profile of the finished sterilised device, characterised to ISO 10993-18, identified no constituent above the analytical evaluation threshold requiring further assessment, and the toxicological risk assessment under ISO 10993-17 concluded X” is.

For documentation prepared for a submission rather than for internal use, the regulatory writing page covers the document structures that reviewers expect, and device risk management covers the risk file on which the evaluation depends.

Implications of implantation beyond 30 days

Thirty days is a threshold with substantive consequences, not an administrative boundary. Al-Zyoud and colleagues, in Materials, treat biodegradation testing as essential where a device is intended for implantation exceeding 30 days 9. That matches the structure of the standards: ISO 10993-9 sets the framework for identifying and quantifying degradation products, with ISO 10993-13, -14 and -15 covering polymers, ceramics and metals respectively.

The practical effect is that a design change extending indicated dwell time from four weeks to six weeks is not a minor change. It moves the device into the long-term contact category, brings degradation characterisation and the chronic end of the toxicology set into scope, and may also change the clinical evidence expectation. Teams frequently make that change for sound clinical reasons and discover the regulatory cost late. The question should be addressed when the indication is drafted.

Degradation is also the point at which the mechanical and biological arguments cease to be separable. A polymer that degrades predictably in bench ageing may degrade differently under cyclic load in vivo, and the degradation products are the subject of the toxicological assessment. If fatigue testing and degradation testing were conducted on differently processed samples, a reviewer is entitled to ask which one represents the device.

Mechanical duty as the primary constraint

For load-bearing devices the material shortlist is usually settled on fatigue before biocompatibility is considered at all, and that ordering is correct 21. Kang and Fang estimate a patient’s step count over 20 years at over 1 × 107 loading cycles, which is the fatigue requirement a hip or knee component has to survive 21. A material that cannot meet that requirement is not a candidate, regardless of its biological profile.

Two consequences follow for the dossier. First, the fatigue argument must be made on the device geometry and surface condition as manufactured, not on polished coupons, because notches, porous coatings and machining marks are where fatigue cracks initiate. Second, the assumed loading spectrum must be defensible against the indicated population. A device indicated for younger, more active patients is required to withstand more cycles than the same device in a frail elderly population, and the justification should state which population the test spectrum represents.

Daniel and colleagues, in Frontiers in Bioengineering and Biotechnology, review the direction of biomedical implant materials — and the recurring theme is that improvements in one property, such as stiffness matching to bone, usually come at a cost elsewhere 5. There is no dominant material. There is a set of trade-offs, and the manufacturer must demonstrate that they were made deliberately.

Surfaces, coatings and nanoscale features

Surface engineering is now the source of much of the differentiation, and it is also the area in which the regulatory position is least settled. Zheng and colleagues, in RSC Advances, note that the European Commission defines nanomaterials as those in which 50% or more of the particles have one or more external dimensions in the 1–100 nm range 17. If a coating, filler or surface treatment on a device meets that definition, the device may fall under different regulatory considerations — in the EU, device classification rules treat devices incorporating nanomaterial differently depending on the potential for internal exposure, which is a classification question to be resolved with a notified body rather than assumed.

Technically, the questions a reviewer asks about a nanostructured surface are the ordinary ones, made more difficult: whether the feature is stable in service or particles can be released under wear and load; what the degradation pathway of a released particle is, and whether the toxicological assessment covers it; and whether the chemical characterisation method detects particulates or only dissolved species. Tang and colleagues, in Progress in Polymer Science, and Hasirci and colleagues, in the Journal of Biomaterials Science, Polymer Edition, survey the materials science; the evaluation methods have advanced more slowly than the materials, and a dossier should state this where it applies 23,26.

Our companion page on nano-biomaterials goes into the materials side in more depth.

Divergence between the two major jurisdictions

The biological evaluation science is largely shared; the regulatory use of it is not. In the United States, the common route for a moderate-risk device is 510(k) clearance on the basis of substantial equivalence to a predicate, and FDA’s guidance on ISO 10993-1 governs how biological evaluation is presented in that submission 2. In the European Union, EU MDR 2017/745 sets general safety and performance requirements in Annex I, of which the chemical, physical and biological properties requirement is the one that bears on materials, and conformity is assessed by a notified body against a classification determined by the Annex VIII rules. There is no European equivalent of substantial equivalence to a predicate as a standalone route.

Two consequences are relevant when a single material dossier is planned for both. The first is that a device class may differ between jurisdictions for the same product, which changes both the conformity assessment route and the clinical evidence expectation; a European class should not be inferred from a US classification 12. The second is that MDR places specific justification obligations on devices containing carcinogenic, mutagenic or reprotoxic substances or endocrine disruptors above a specified concentration in certain invasive devices — an obligation with no direct US analogue, and one that is a material selection question, not a labelling one.

The clinical evidence requirements of MDR are substantial enough to warrant separate treatment, which is provided in regulatory and ethical challenges for medical devices. Whichever markets are targeted, this article should be treated as a description of what the instruments require, and the applicable route should be confirmed with the regulatory affairs function; Pubrica does not certify compliance.

Writing a reviewable biological evaluation

The difference between a biological evaluation section that passes review and one that generates a deficiency letter rarely lies in the testing. It lies in whether a reader can reconstruct the reasoning: what the device is, which cell of the contact grid it occupies, which endpoints follow, which were tested, which were justified from existing data, and on what basis. The weak version compresses all of this into one sentence naming the standard. The strong version is four sentences longer and anticipates the questions.

The same biocompatibility conclusion, written two ways

Cites the standard generically

The device is manufactured from medical-grade titanium alloy. Biocompatibility has been established in accordance with ISO 10993 standards, and the material has a long history of safe clinical use in comparable devices. No adverse biological effects are expected.

Which contact category? Unstated, so the reviewer cannot tell which endpoint matrix applies.

Which endpoints were addressed, and how? “In accordance with ISO 10993” covers a framework, not a result.

Tested, or justified from existing data? Not distinguished — and the justification is the part under review.

Why is history of use relevant? Biological response is a property of the finished sterilised device, not of the raw alloy.

Is haemocompatibility missing or inapplicable? A blank row reads as an omission.

Names the categorisation and the endpoint set

The device is a Ti-6Al-4V ELI bone screw intended to remain implanted indefinitely, which places it in the implant device category with tissue and bone contact and long-term (over 30 days) duration under ISO 10993-1. Biological evaluation was conducted within the risk management process and addressed cytotoxicity, sensitisation, irritation, acute and subchronic systemic toxicity, material-mediated pyrogenicity, genotoxicity, local effects after implantation, chronic toxicity and carcinogenicity. Cytotoxicity, sensitisation, irritation and implantation were addressed by testing on the finished sterilised device. Systemic toxicity, genotoxicity, chronic toxicity and carcinogenicity were addressed by chemical characterisation of the finished device to ISO 10993-18 and toxicological risk assessment to ISO 10993-17; the per-endpoint justifications, including the analytical evaluation threshold applied and the uncertainty factors used, are given in Section 4.3. Degradation was characterised under ISO 10993-9 and ISO 10993-15 because contact exceeds 30 days. Haemocompatibility is not applicable: the device has no blood-path contact in the indicated use.

The contact category and duration are stated, so the endpoint matrix is auditable.

Every applicable endpoint is named, and each is marked as tested or justified.

The justification route is specified by standard part, with the thresholds and uncertainty factors cross-referenced rather than asserted.

Degradation is tied explicitly to the 30-day duration trigger.

A non-applicable endpoint is called non-applicable, with the reason.

The second version is not better written; it is the same conclusion made verifiable. Each addition closes a question that a reviewer would otherwise raise as a deficiency, and the costly component — the testing — is identical in both. What changes is whether the reader can follow the reasoning.

Limitations of the current evidence

Two gaps merit explicit statement. First, there is no accepted quantitative method for translating a chemical characterisation result into a clinical risk for most implant materials; ISO 10993-17 provides a framework for toxicological risk assessment, but the choice of allowable limits and the uncertainty factors applied remain matters of expert judgement with which reviewers can and do disagree. A file that acknowledges where its assessment rests on judgement is in a stronger position than one that presents the output as a measurement.

Second, long-term material performance evidence is weaker than the volume of implanted devices would suggest. Hoogervorst and colleagues, in the International Journal of Health Policy and Management, reviewed European cardiovascular and orthopaedic registries for their usefulness in regulatory evaluation of device safety and performance across the implant lifecycle, and found the reporting of registry structure and methodology highly variable — which limits how far registry data can substitute for prospective evidence on a new material 11. Where registry or literature evidence is to be relied upon for a material, a systematic review conducted rigorously, rather than a narrative citation list, should be planned, because a reviewer will ask how the evidence was identified.

Key points

Key points

Material selection for a device is determined by three constraints in sequence: mechanical duty, contact category and supply-chain stability. Fatigue requirements of the order of 1 × 107 cycles over twenty years narrow the shortlist before biological considerations arise. Contact category and duration under ISO 10993-1 then determine the endpoint set, and the 30-day duration boundary brings degradation and chronic toxicology into scope. ISO 10993-1 does not prescribe a test list: it requires a risk-based evaluation in which each endpoint is either tested or justified in writing, and these justifications are the focus of reviewer scrutiny. Classification and route differ between FDA and EU MDR 2017/745 for the same device, and both should be confirmed with the regulatory affairs function rather than inferred from one another.

Application to your study

Application to your study

  1. Record the contact category and duration first. Determine the nature of contact and the duration band from the indication as it will be labelled, including the worst case a clinician could reasonably follow rather than the typical case.
  2. Construct an endpoint table with three columns: applicability, method of addressing the endpoint, and justification reference. Every endpoint requires a row. Non-applicable endpoints require a row and a stated reason rather than a blank.
  3. Determine whether the indicated duration exceeds 30 days. If it does, degradation characterisation and the chronic end of the toxicology set are in scope; where the duration is close to the boundary, the decision should be made deliberately rather than identified during review.
  4. Confirm that fatigue testing used device geometry and the as-manufactured surface condition. Data from polished coupons cannot answer a question about a porous-coated stem.
  5. Determine whether any coating, filler or surface treatment meets the nanomaterial definition. A proportion of fifty per cent or more of particles with an external dimension in the 1–100 nm range alters the EU classification discussion, which should be resolved with the notified body.
  6. Determine the device class separately in each target market. This involves the US classification regulation and submission route, and the EU MDR Annex VIII rules; neither should be inferred from the other.
  7. Identify every foreseeable material or process change and estimate the cost of re-evaluation at the outset. A resin grade substitution reopens chemical characterisation; establishing this before single-sourcing is less costly than discovering it afterwards.
  8. Obtain regulatory affairs approval of the test plan against the current guidance version. Guidance documents are revised, and a plan based on a superseded version represents a scheduling risk.

Frequently asked questions

Not directly. ISO 10993-1 requires biological evaluation of a medical device within a risk management process, and it organises the applicable biological endpoints by the nature of body contact and the duration of contact. The endpoint matrices indicate which endpoints should be considered for a given contact category — they do not mandate a fixed battery of tests. For each applicable endpoint, the manufacturer may either test or provide a justification that existing data, chemical characterisation under ISO 10993-18 and toxicological risk assessment under ISO 10993-17 adequately address it. FDA’s 2023 guidance on the use of ISO 10993-1 describes what the Agency expects in that justification. The current version should be confirmed with the regulatory affairs function.

Thirty days is the boundary between prolonged and long-term contact under ISO 10993-1, and crossing it widens the evaluation. Al-Zyoud and colleagues, in Materials, treat biodegradation testing as essential where implantation exceeds 30 days, and the standards are structured in the same way: ISO 10993-9 frames identification and quantification of degradation products, with ISO 10993-13, -14 and -15 covering polymers, ceramics and metals. The chronic end of the toxicology set — chronic toxicity and carcinogenicity — also becomes relevant. In practice, a change to indicated dwell time is therefore a regulatory change, not only a clinical one, and it should be costed when the indication is drafted.

Partly, and only with a written argument. Biological response is a property of the finished, sterilised device in its contact configuration, not of the raw material — so surface finish, cleaning agent residues, sterilisation route and processing history must all be addressed. Where existing data are relied upon, the data should be named, the reasons they transfer to this device and this contact category stated, and the assessment recorded per endpoint. Ti-6Al-4V is a well-populated comparison set, accounting for about 45% of titanium-based bioimplant production according to Kang and Fang in Advances in Manufacturing, but a populated comparison set is an argument that must still be made, not a waiver.

Kang and Fang, in Advances in Manufacturing, estimate a patient’s step count over 20 years at over 1 × 107 loading cycles, and that figure sets the fatigue requirement for load-bearing implants. Two qualifications matter for a dossier. The test article should reflect the device geometry and as-manufactured surface condition, because fatigue cracks initiate at notches, machining marks and coating interfaces rather than on polished coupons. And the loading spectrum should be defensible against the indicated population: a device indicated for younger, more active patients is being asked for more and larger cycles than the same device used in a frail elderly population.

In the European Union it can be. Zheng and colleagues, in RSC Advances, record the European Commission definition of nanomaterials as those where 50% or more of the particles have one or more external dimensions in the 1–100 nm range, and EU MDR 2017/745 classification rules treat devices incorporating nanomaterial according to the potential for internal exposure. Whether a coating falls within that definition is a measurement question with classification consequences, and it should be resolved with the notified body rather than assumed. Technically, the evaluation questions are the usual ones made more difficult: particle release under wear and load, the degradation pathway of a released particle, and whether the characterisation method detects particulates at all.

The science transfers; the regulatory argument does not transfer wholesale. FDA reviews biological evaluation within a premarket submission whose route depends on US classification, commonly 510(k) substantial equivalence for moderate-risk devices. EU MDR 2017/745 requires conformity with the general safety and performance requirements in Annex I, assessed by a notified body against a class determined by the Annex VIII rules, with no standalone predicate-equivalence route. Device class can differ between the two markets for the same product, and MDR imposes specific justification obligations for certain substances of concern that have no direct US analogue. The recommended approach is a common technical core with jurisdiction-specific arguments added to it.

Less than its volume suggests. Hoogervorst and colleagues, in the International Journal of Health Policy and Management, systematically reviewed European cardiovascular and orthopaedic registries for their usefulness in regulatory evaluation of device safety and performance, and found reporting of registry structure and methodology highly variable. That variability limits the extent to which a registry can support a claim about a new material, particularly where the registry does not capture the material variant or the failure mode of interest. Where registry or published evidence is to be relied upon, it should be identified through a documented search rather than a narrative citation list, because a reviewer will ask how it was found.

The manufacturer’s regulatory affairs function and, in the European Union, its notified body. Pubrica describes what the instruments require and assists in constructing and writing the argument; Pubrica does not certify compliance, and no consultancy can. An effective division of labour is as follows: engineering is responsible for the mechanical and processing case, toxicology for the endpoint assessment and the uncertainty factors, regulatory affairs for the classification and route determination and the currency of the guidance applied, and the writing team for making the whole argument legible to a reviewer who lacks the project context.

References

  1. U.S. Food and Drug Administration. Container Closure Systems for Human Drugs and Biological Products (draft guidance). U.S. Food and Drug Administration. 2026. read 9 October 2026. packagingdigest.com
  2. U.S. Food and Drug Administration (CDRH, CBER). Use of International Standard ISO 10993-1, "Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process". U.S. Food and Drug Administration. 2023. read 9 October 2026. fda.gov
  3. International Council for Harmonisation; U.S. Food and Drug Administration (CDER/CBER). Guidance for Industry Q8(R2) Pharmaceutical Development. U.S. Department of Health and Human Services, Food and Drug Administration. 2009;Revision 2. read 9 October 2026. fda.gov
  4. Huang Y, Liu H, Lin Y, Hu J, Zou L, Chen S, Chen O, Yi X, Wang L. Micro-LEDs in biomedicine: from implantable optogenetics to intelligent theranostics. Journal of Semiconductors. 2026;47(8):081606. doi:10.1088/1674-4926/26050037 read 9 October 2026. doi.org/10.1088/1674-4926/26050037
  5. Daniel SA, Suya Prem Anand P, Jesuarockiam N, Tabrej K, Shabir Hussain K. Advancement in biomedical implant materials-a mini review. Frontiers in Bioengineering and Biotechnology. 2024;12. doi:10.3389/fbioe.2024.1400918 read 9 October 2026. doi.org/10.3389/fbioe.2024.1400918
  6. Metuh P, Petersen PM, Ou Y. Recent Advances in Wireless Optoelectronic Biomedical Implants. Laser & Photonics Reviews. 2024;18(12):2300752. doi:10.1002/lpor.202300752 read 9 October 2026. doi.org/10.1002/lpor.202300752
  7. Estape Senti M, Garcia Del Valle L, Schiffelers RM. mRNA delivery systems for cancer immunotherapy: Lipid nanoparticles and beyond. Advanced Drug Delivery Reviews. 2024;206:1-17. doi:10.1016/j.addr.2024.115190 read 9 October 2026. doi.org/10.1016/j.addr.2024.115190
  8. Everhart AO, Sen S, Stern AD, et al. Association between regulatory submission characteristics and recalls of medical devices receiving 510(k) clearance. JAMA. 2023;329:144-156. read 9 October 2026. tctmd.com
  9. Al-Zyoud W, Haddadin D, Hasan SA, Jaradat H, Kanoun O. Biocompatibility Testing for Implants: A Novel Tool for Selection and Characterization. Materials. 2023;16(21):6881. doi:10.3390/ma16216881 read 9 October 2026. doi.org/10.3390/ma16216881
  10. Wu W, Wang L, Shen G. Flexible photoplethysmographic sensing devices for intelligent medical treatment. Journal of Materials Chemistry C. 2023;11:97-112. doi:10.1039/D2TC03318F read 9 October 2026. doi.org/10.1039/D2TC03318F
  11. Hoogervorst LA, Geurkink TH, Lubbeke A, et al. Quality and Utility of European Cardiovascular and Orthopaedic Registries for the Regulatory Evaluation of Medical Device Safety and Performance Across the Implant Lifecycle: A Systematic Review. International Journal of Health Policy and Management. 2023;12(1):1-11. doi:10.34172/ijhpm.2023.7648 read 9 October 2026. doi.org/10.34172/ijhpm.2023.7648
  12. Kearney B, McDermott O. The Challenges for Manufacturers of the Increased Clinical Evaluation in the European Medical Device Regulations: A Quantitative Study. Therapeutic Innovation & Regulatory Science. 2023. doi:10.1007/s43441-023-00527-z read 9 October 2026. doi.org/10.1007/s43441-023-00527-z
  13. Kadakia KT, Dhruva SS, Caraballo C, et al. Use of recalled devices in new device authorizations under the US Food and Drug Administration's 510(k) pathway and risk of subsequent recalls. JAMA. 2023;329:136-143. read 9 October 2026. tctmd.com
  14. Liu R, Luo C, Pang Z, et al. Advances of nanoparticles as drug delivery systems for disease diagnosis and treatment. Chinese Chemical Letters. 2022. doi:10.1016/j.cclet.2022.05.032 read 9 October 2026. doi.org/10.1016/j.cclet.2022.05.032
  15. Zhao H. Optogenetic Implants. Handbook of Biochips. 2022:179-206. doi:10.1007/978-1-4614-3447-4_48 read 9 October 2026. doi.org/10.1007/978-1-4614-3447-4_48
  16. Zheng X, Xie J, Zhang X, Sun W, Zhao H, Li Y, Wang C. An overview of polymeric nanomicelles in clinical trials and on the market. Chinese Chemical Letters. 2021;32(1):243-257. doi:10.1016/j.cclet.2020.11.029 read 9 October 2026. doi.org/10.1016/j.cclet.2020.11.029
  17. Zheng X, Zhang P, Fu Z, Meng S, Dai L, Yang H. Applications of nanomaterials in tissue engineering. RSC Advances. 2021;11:19041-19058. doi:10.1039/d1ra01849c read 9 October 2026. doi.org/10.1039/d1ra01849c
  18. Lee I, Park N, Lee H, Hwang C, Kim JH, Park S. Systematic Review on Human Skin-Compatible Wearable Photoplethysmography Sensors. Applied Sciences. 2021;11(5):2313. doi:10.3390/app11052313 read 9 October 2026. doi.org/10.3390/app11052313
  19. Kumar SSD, Abrahamse H. Advancement of nanobiomaterials to deliver natural compounds for tissue engineering applications. International Journal of Molecular Sciences. 2020;21(18):1-27. doi:10.3390/ijms21186752 read 9 October 2026. doi.org/10.3390/ijms21186752
  20. Wouters OJ, McKee M, Luyten J. Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018. JAMA. 2020;323(9):844-853. doi:10.1001/jama.2020.1166 read 9 October 2026. doi.org/10.1001/jama.2020.1166
  21. Kang CW, Fang FZ. State of the art of bioimplants manufacturing: part I. Advances in Manufacturing. 2018;6:20-40. doi:10.1007/s40436-017-0207-4 read 9 October 2026. doi.org/10.1007/s40436-017-0207-4
  22. Muskens IS, Gupta S, Hulsbergen A, Moojen WA, Broekman MLD. Introduction of Novel Medical Devices in Surgery: Ethical Challenges of Current Oversight and Regulation. Journal of American College of Surgeons. 2017;225:558-565. read 9 October 2026. scholarlypublications.universiteitleiden.nl
  23. Tang Z, He C, Tian H, Ding J, Hsiao BS, Chu B, Chen X. Polymeric nanostructured materials for biomedical applications. Progress in Polymer Science. 2016;60:86-128. doi:10.1016/j.progpolymsci.2016.05.005 read 9 October 2026. doi.org/10.1016/j.progpolymsci.2016.05.005
  24. Carli Lorenzini G, Olsson A. DESIGN TOWARDS BETTER LIFE EXPERIENCE: CLOSING THE GAP BETWEEN PHARMACEUTICAL PACKAGING DESIGN AND ELDERLY PEOPLE. DS 80-9 Proceedings of the 20th International Conference on Engineering Design (ICED 15). 2015;9:065-076. read 9 October 2026. designsociety.org
  25. Johnson J, Rogers W. Innovative surgery: The ethical challenges. Journal of Medical Ethics. 2012;38(1):9-12. doi:10.1136/jme.2010.042150 read 9 October 2026. doi.org/10.1136/jme.2010.042150
  26. Hasirci V, Vrana E, Zorlutuna P, Ndreu A, Yilgor P, Basmanav FB, Aydin E. Nanobiomaterials: a review of the existing science and technology, and new approaches. Journal of Biomaterials Science, Polymer Edition. 2006;17(11):1241-1268. doi:10.1163/156856206778667442 read 9 October 2026. doi.org/10.1163/156856206778667442

Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.

How to cite this article

Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.

Pubrica Academy. (2026, October 9). Selecting Materials for a Medical Device: Biological Evaluation Requirements under ISO 10993-1. Pubrica. https://pubrica.com/academy/medical-writing/selecting-materials-for-medical-device-industry/

This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.

Material selection and biological evaluation planning sheet

This sheet should be completed before the material is designed in, not afterwards. Any line that cannot be answered represents a question a reviewer will ask. The completed sheet should be kept in the design history file — the justification column is the part that is read.

MATERIAL SELECTION AND BIOLOGICAL EVALUATION PLANNING SHEET
Device: ______________________   Material / grade: ______________________
Finished-device configuration (surface finish, coatings, sterilisation route): __________

1. CONTACT CATEGORISATION  (ISO 10993-1)
   Nature of body contact ....... [ ] surface  [ ] externally communicating  [ ] implant
     sub-category: ______________________
   Duration of contact .......... [ ] limited (<=24 h)  [ ] prolonged (>24 h to 30 d)
                                  [ ] long-term (>30 d)
   Duration taken from: [ ] labelled indication  [ ] worst case a clinician may follow
   Does indicated duration cross 30 days? [ ] no  [ ] yes -> degradation + chronic set in scope

2. ENDPOINT TABLE  (one row per endpoint; no blanks)
   Endpoint                        Applicable?  Addressed by          Justification ref
   Material characterisation (-18)  ___         test / existing data   ___________
   Toxicological risk assess (-17)  ___         ___________            ___________
   Cytotoxicity (-5)                ___         ___________            ___________
   Sensitisation (-10)              ___         ___________            ___________
   Irritation (-10)                 ___         ___________            ___________
   Acute systemic toxicity (-11)    ___         ___________            ___________
   Material-mediated pyrogenicity   ___         ___________            ___________
   Subacute / subchronic (-11)      ___         ___________            ___________
   Genotoxicity (-3)                ___         ___________            ___________
   Implantation / local effects (-6) ___        ___________            ___________
   Haemocompatibility (-4)          ___         ___________            ___________
   Chronic toxicity                 ___         ___________            ___________
   Carcinogenicity (-3)             ___         ___________            ___________
   Degradation (-9 / -13 / -14 / -15) ___       ___________            ___________

3. MECHANICAL DUTY
   [ ] Required cycles stated, with the source of the loading spectrum
   [ ] Indicated population that the spectrum represents: ______________________
   [ ] Test articles used device geometry and as-manufactured surface condition
   [ ] Fatigue and degradation test articles were processed identically

4. NANOMATERIAL SCREEN
   [ ] Any coating, filler or surface treatment assessed against the 1-100 nm /
       50%-of-particles definition.  Result: ______________________
   [ ] If yes: potential for internal exposure assessed; notified body consulted

5. JURISDICTION  (complete once per target market; do not infer one from another)
   Market: __________   Class: __________   Route: __________
   Instrument relied on: ______________________
   Substances-of-concern obligations applicable? [ ] no  [ ] yes  details: __________
   Regulatory affairs sign-off on guidance version applied: __________  date: ______

6. CHANGE CONTROL
   Foreseeable material / supplier / process changes: ______________________
   Re-evaluation triggered by each, and its estimated cost: ______________________

Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.

How Pubrica can help

Pubrica’s medical writing and regulatory writing teams construct the biological evaluation argument from the contact categorisation outward, so that every endpoint in the file is either tested or justified in writing with the supporting data identified. The teams also conduct the documented literature and registry searches on which an evidence-based justification depends, and write the sections so that a reviewer without project context can follow the reasoning. Pubrica describes what the instruments require and assists in evidencing it; the manufacturer’s regulatory affairs function and notified body determine compliance.

Find something else

Search the Pubrica Academy

Access is free and requires no account. Enter a topic, or open the full library to filter by category, sub-topic or resource type.

Pubrica can review a device description and indication and map the contact categorisation and endpoint set in collaboration with the manufacturer.

A scoping assessment is free and takes two business days. It provides a written assessment of what the work requires and which specialist would undertake it.

Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.